Sugammadex is a modified
γ-cyclodextrin active pharmaceutical
ingredient (API) that is used as a reversal agent for neuromuscular
blockade drugs in general anesthesia. The open structure of the cyclodextrin
molecule yields a multitude of solid forms, and to date, more than
12 different mixed methanol solvate/hydrate forms have been characterized.
Historically, the kinetic form (type 1) was manufactured to ensure
that the solids could be dried successfully using only heat and vacuum
to meet the specifications for residual solvents. Isolation of the
thermodynamic form (type 2) was avoided due to the inability to remove
process solvents to desired levels during drying and the subsequent
need to rework the solids. To meet increasing product demand through
improved robustness, the process was redesigned to manufacture the
thermodynamic form (type 2). Therefore, an improved drying process
had to be developed to enable meeting residual solvent levels of the
final API at a large scale. Small-scale drying experiments were performed
using a custom, in-house, process analytical technology-enabled drying
platform to visualize the real-time evolution of the process solvents
and water from the solids and to monitor form change. The mechanism
for solvent removal in this case was found to be unique since it was
independent of API crystallinity. The key element for successful drying
was the displacement of solvent by water molecules, regardless of
whether the crystal structure remained intact or collapsed. A predictive
model was developed through design of experiments including three-factor
interactions of drying humidity, temperature, and pressure, and the
model was used to define the operating space to ensure successful
drying. The humid drying conditions identified in this study were
implemented across scales to ensure that residual solvent specifications
were achieved regardless of the crystalline form generated.